换肤

苑东生物

i问董秘

A03361

主营介绍

  • 主营业务：

    化学原料药和化学药制剂的研究、生产与销售

  • 产品类型：

    化学原料药、化学药制剂

  • 产品名称：

    乌苯美司胶囊 、 伊班膦酸钠注射液 、 富马酸比索洛尔片 、 注射用复方甘草酸苷 、 盐酸纳美芬注射液 、 布洛芬注射 、 枸橼酸咖啡因注射液

  • 经营范围：

    生产：小容量注射剂、冻干粉针剂、片剂、硬胶囊剂、片剂（抗肿瘤类）；生物及化学技术咨询；生物技术开发服务；医药技术研发；医药技术咨询；医药技术转让；医药技术服务；信息咨询（投资咨询、中介服务除外）；企业管理咨询；货物、技术进出口。（依法须经批准的项目，经相关部门批准后方可开展经营活动）。（药品生产许可证有效期至2020年12月31日）。

主营构成分析

报告期
报告期
{"2019-12-31":{"YYSR":{"2":[["\u5236\u5242\u9500\u552e","84833.31"],["\u539f\u6599\u836f\u9500\u552e","6384.88"],["\u6280\u672f\u670d\u52a1","3043.40"]],"3":[["\u534e\u4e1c\u5730\u533a","26456.34"],["\u534e\u5317\u5730\u533a","19815.33"],["\u897f\u5357\u5730\u533a","19482.01"],["\u534e\u5357\u5730\u533a","12328.55"],["\u534e\u4e2d\u5730\u533a","8531.06"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7648.31]]},"YYCB":{"2":[["\u5236\u5242\u9500\u552e","7439.05"],["\u539f\u6599\u836f\u9500\u552e","1471.00"],["\u6280\u672f\u670d\u52a1","69.54"]],"3":[["\u534e\u4e1c\u5730\u533a","2326.73"],["\u534e\u5317\u5730\u533a","1940.39"],["\u897f\u5357\u5730\u533a","1745.98"],["\u534e\u5357\u5730\u533a","852.53"],["\u534e\u4e2d\u5730\u533a","1058.57"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1055.39]]},"LRBL":{"2":[["\u5236\u5242\u9500\u552e","90.75"],["\u539f\u6599\u836f\u9500\u552e","5.76"],["\u6280\u672f\u670d\u52a1","3.49"]],"3":[["\u534e\u4e1c\u5730\u533a","28.29"],["\u534e\u5317\u5730\u533a","20.96"],["\u897f\u5357\u5730\u533a","20.80"],["\u534e\u5357\u5730\u533a","13.46"],["\u534e\u4e2d\u5730\u533a","8.76"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7.73]]}},"2018-12-31":{"YYSR":{"2":[["\u5236\u5242\u9500\u552e","69645.80"],["\u539f\u6599\u836f\u9500\u552e","4455.91"],["\u6280\u672f\u670d\u52a1","2694.27"]],"3":[["\u534e\u4e1c\u5730\u533a","20254.29"],["\u897f\u5357\u5730\u533a","16092.54"],["\u534e\u5317\u5730\u533a","15984.64"],["\u534e\u5357\u5730\u533a","12245.43"],["\u534e\u4e2d\u5730\u533a","6986.45"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",5232.64]]},"YYCB":{"2":[["\u5236\u5242\u9500\u552e","7375.03"],["\u539f\u6599\u836f\u9500\u552e","1268.69"],["\u6280\u672f\u670d\u52a1","58.65"]],"3":[["\u534e\u4e1c\u5730\u533a","1996.67"],["\u897f\u5357\u5730\u533a","1639.76"],["\u534e\u5317\u5730\u533a","1906.86"],["\u534e\u5357\u5730\u533a","1199.63"],["\u534e\u4e2d\u5730\u533a","940.82"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",1018.63]]},"LRBL":{"2":[["\u5236\u5242\u9500\u552e","91.45"],["\u539f\u6599\u836f\u9500\u552e","4.68"],["\u6280\u672f\u670d\u52a1","3.87"]],"3":[["\u534e\u4e1c\u5730\u533a","26.81"],["\u897f\u5357\u5730\u533a","21.22"],["\u534e\u5317\u5730\u533a","20.67"],["\u534e\u5357\u5730\u533a","16.22"],["\u534e\u4e2d\u5730\u533a","8.88"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",6.19]]}},"2017-12-31":{"YYSR":{"2":[["\u5236\u5242\u9500\u552e","44305.34"],["\u539f\u6599\u836f\u9500\u552e","2187.02"],["\u6280\u672f\u670d\u52a1","934.59"]],"3":[["\u897f\u5357\u5730\u533a","13200.72"],["\u534e\u4e1c\u5730\u533a","12521.74"],["\u534e\u5317\u5730\u533a","9249.41"],["\u534e\u5357\u5730\u533a","5931.35"],["\u534e\u4e2d\u5730\u533a","2849.38"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",3674.36]]},"YYCB":{"2":[["\u5236\u5242\u9500\u552e","6264.69"],["\u539f\u6599\u836f\u9500\u552e","809.24"],["\u6280\u672f\u670d\u52a1",""]],"3":[["\u897f\u5357\u5730\u533a","1724.14"],["\u534e\u4e1c\u5730\u533a","1729.27"],["\u534e\u5317\u5730\u533a","1277.81"],["\u534e\u5357\u5730\u533a","957.26"],["\u534e\u4e2d\u5730\u533a","609.05"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",776.39]]},"LRBL":{"2":[["\u5236\u5242\u9500\u552e","96.50"],["\u539f\u6599\u836f\u9500\u552e","3.50"],["\u6280\u672f\u670d\u52a1",""]],"3":[["\u897f\u5357\u5730\u533a","28.44"],["\u534e\u4e1c\u5730\u533a","26.75"],["\u534e\u5317\u5730\u533a","19.75"],["\u534e\u5357\u5730\u533a","12.33"],["\u534e\u4e2d\u5730\u533a","5.55"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7.18]]}}}
{"YYSR":{"chartWrap2":[{"name":"\u5236\u5242\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[84833.31,69645.8,44305.34],"columnData":[90,90.69,93.42],"unit":["8.48\u4ebf","6.96\u4ebf","4.43\u4ebf"]},{"name":"\u539f\u6599\u836f\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[6384.88,4455.91,2187.02],"columnData":[6.77,5.8,4.61],"unit":["6384.88\u4e07","4455.91\u4e07","2187.02\u4e07"]},{"name":"\u6280\u672f\u670d\u52a1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[3043.4,2694.27,934.59],"columnData":[3.23,3.51,1.97],"unit":["3043.40\u4e07","2694.27\u4e07","934.59\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[26456.34,20254.29,12521.74],"columnData":[28.07,26.37,26.4],"unit":["2.65\u4ebf","2.03\u4ebf","1.25\u4ebf"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[19815.33,15984.64,9249.41],"columnData":[21.02,20.81,19.5],"unit":["1.98\u4ebf","1.60\u4ebf","9249.41\u4e07"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[19482.01,16092.54,13200.72],"columnData":[20.67,20.95,27.83],"unit":["1.95\u4ebf","1.61\u4ebf","1.32\u4ebf"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[12328.55,12245.43,5931.35],"columnData":[13.08,15.95,12.51],"unit":["1.23\u4ebf","1.22\u4ebf","5931.35\u4e07"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[8531.06,6986.45,2849.38],"columnData":[9.05,9.1,6.01],"unit":["8531.06\u4e07","6986.45\u4e07","2849.38\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[7648.31,5232.64,3674.36],"columnData":[8.11,6.82,7.75],"unit":["7648.31\u4e07","5232.64\u4e07","3674.36\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"\u5236\u5242\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[7439.05,7375.03,6264.69],"columnData":[82.84,84.75,88.56],"unit":["7439.05\u4e07","7375.03\u4e07","6264.69\u4e07"]},{"name":"\u539f\u6599\u836f\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[1471,1268.69,809.24],"columnData":[16.38,14.58,11.44],"unit":["1471.00\u4e07","1268.69\u4e07","809.24\u4e07"]},{"name":"\u6280\u672f\u670d\u52a1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[69.54,58.65,0],"columnData":[0.77,0.67,0],"unit":["69.54\u4e07","58.65\u4e07","0.00"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[2326.73,1996.67,1729.27],"columnData":[25.91,22.94,24.45],"unit":["2326.73\u4e07","1996.67\u4e07","1729.27\u4e07"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[1940.39,1906.86,1277.81],"columnData":[21.61,21.91,18.06],"unit":["1940.39\u4e07","1906.86\u4e07","1277.81\u4e07"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[1745.98,1639.76,1724.14],"columnData":[19.44,18.84,24.37],"unit":["1745.98\u4e07","1639.76\u4e07","1724.14\u4e07"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[852.53,1199.63,957.26],"columnData":[9.49,13.79,13.53],"unit":["852.53\u4e07","1199.63\u4e07","957.26\u4e07"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[1058.57,940.82,609.05],"columnData":[11.79,10.81,8.61],"unit":["1058.57\u4e07","940.82\u4e07","609.05\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[1055.39,1018.63,776.39],"columnData":[11.75,11.7,10.97],"unit":["1055.39\u4e07","1018.63\u4e07","776.39\u4e07"]}]},"LRBL":{"chartWrap2":[{"name":"\u5236\u5242\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[90.75,91.45,96.5],"columnData":[90.75,91.45,96.5],"unit":["90.75\u4e07","91.45\u4e07","96.50\u4e07"]},{"name":"\u539f\u6599\u836f\u9500\u552e","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[5.76,4.68,3.5],"columnData":[5.76,4.68,3.5],"unit":["5.76\u4e07","4.68\u4e07","3.50\u4e07"]},{"name":"\u6280\u672f\u670d\u52a1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[3.49,3.87,0],"columnData":[3.49,3.87,0],"unit":["3.49\u4e07","3.87\u4e07","0.00"]}],"chartWrap3":[{"name":"\u534e\u4e1c\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[28.29,26.81,26.75],"columnData":[28.29,26.81,26.75],"unit":["28.29\u4e07","26.81\u4e07","26.75\u4e07"]},{"name":"\u534e\u5317\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[20.96,20.67,19.75],"columnData":[20.96,20.67,19.75],"unit":["20.96\u4e07","20.67\u4e07","19.75\u4e07"]},{"name":"\u897f\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[20.8,21.22,28.44],"columnData":[20.8,21.22,28.44],"unit":["20.80\u4e07","21.22\u4e07","28.44\u4e07"]},{"name":"\u534e\u5357\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[13.46,16.22,12.33],"columnData":[13.46,16.22,12.33],"unit":["13.46\u4e07","16.22\u4e07","12.33\u4e07"]},{"name":"\u534e\u4e2d\u5730\u533a","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[8.76,8.88,5.55],"columnData":[8.76,8.88,5.55],"unit":["8.76\u4e07","8.88\u4e07","5.55\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-12-31","2018-12-31","2017-12-31"],"lineData":[7.73,6.19,7.18],"columnData":[7.73,6.19,7.18],"unit":["7.73\u4e07","6.19\u4e07","7.18\u4e07"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 制剂销售 8.48亿 90.00% 7439.05万 82.84% 90.75% 91.23%
原料药销售 6384.88万 6.77% 1471.00万 16.38% 5.76% 76.96%
技术服务 3043.40万 3.23% 69.54万 0.77% 3.49% 97.71%
按地区 华东地区 2.65亿 28.07% 2326.73万 25.91% 28.29% 91.21%
华北地区 1.98亿 21.02% 1940.39万 21.61% 20.96% 90.21%
西南地区 1.95亿 20.67% 1745.98万 19.44% 20.80% 91.04%
华南地区 1.23亿 13.08% 852.53万 9.49% 13.46% 93.08%
华中地区 8531.06万 9.05% 1058.57万 11.79% 8.76% 87.59%
东北地区 5103.03万 5.41% 624.97万 6.96% 5.25% 87.75%
西北地区 2134.25万 2.26% 156.26万 1.74% 2.32% 92.68%
海外地区 411.03万 0.44% 274.16万 3.05% 0.16% 33.30%

董事会经营评述

　　（一）盈利能力总体分析.
　　　2017年至2019年，随着公司业务规模的扩大，公司营业收入保持了较快增长，其中2018年较2017年增长29,242.06万元，增长率为61.39%；2019年较2018年增长17,847.66万元，增长率为23.22%。
　　报告期内，公司扣非归母净利润亦保持了增长，2019年较2017年扣非归母净利润增长3,861.53万元，增幅78.42%。公司净利润的增长主要是得益于公司营业收入的快速增长。
　　（二）营业收入构成及变动分析
　　1、营业收入总体分析
　　（1）营业收入总体构成
　　报告期内公司营业收入保持较快增长，主营业务收入占营业收入的比重均在... 查看全部▼

　　（一）盈利能力总体分析.
　　　2017年至2019年，随着公司业务规模的扩大，公司营业收入保持了较快增长，其中2018年较2017年增长29,242.06万元，增长率为61.39%；2019年较2018年增长17,847.66万元，增长率为23.22%。
　　报告期内，公司扣非归母净利润亦保持了增长，2019年较2017年扣非归母净利润增长3,861.53万元，增幅78.42%。公司净利润的增长主要是得益于公司营业收入的快速增长。
　　（二）营业收入构成及变动分析
　　1、营业收入总体分析
　　（1）营业收入总体构成
　　报告期内公司营业收入保持较快增长，主营业务收入占营业收入的比重均在99%以上，主营业务突出。报告期内，公司其他业务收入均为定制加工服务收入。
　　（2）主营业务收入变动分析
　　公司主营业务收入2018年较2017年增加了61.92%、2019年较2018年增长了22.74%，增长速度较快，主要是由于报告期内公司持续加大市场推广力度，主要产品的销量逐年增加，同时“两票制”政策实施后，公司主要产品的销售价公司主营业务收入2018年较2017年增加了61.92%、2019年较2018年增长了22.74%，增长速度较快，主要是由于报告期内公司持续加大市场推广力度，主要产品的销量逐年增加，同时“两票制”政策实施后，公司主要产品的销售价
　　（1）主营业务收入产品结构分析
　　报告期内，公司九成以上的主营业务收入来源于化学药制剂的销售收入。
　　报告期各期公司营业收入保持了持续增长态势。报告期内公司销售的主要产品为富马酸比索洛尔片、伊班膦酸钠注射液、乌苯美司胶囊、注射用复方甘草酸苷、盐酸纳美芬注射液、枸橼酸咖啡因注射液和布洛芬注射液等七大化学药制剂产品，该七种产品2017年、2018年和2019年收入合计金额占主营业务收入总额的比重分别为80.19%、82.83%和85.53%，主要产品的销售情况基本保持稳定。
　　除了合作产品盐酸纳美芬注射液等产品由于受两票制的影响导致合作方式发生变化以外，报告期内公司主要的产品均保持了稳定增长，与公司的经营规模逐步扩大保持了一致。
　　（2）技术服务收入说明：
　　公司的技术服务收入中，包括2018年至2019年公司向上市公司浙江亚太药业股份有限公司收取的CX3002产品技术合作开发收入，以及2019年确认的上市公司哈尔滨誉衡药业股份有限公司解毒降脂胶囊技术转让收入。除此以外，其他技术服务收入均系公司向业务合作方成都天台山、普德药业收取的合作产品技术使用费收入，有关合作产品的收入、成本及毛利率分析的具体情况。公司的合作产品技术服务收入系按合作方向客户发货的合作产品数量收取，单支产品技术服务收费标准根据两票制实施前相关产品的盈利水平并结合公司向合作方提供服务情况予以确定。
　　公司在发展初期通过与生产企业的合作加速研发成果的产业化，促进了发展；而合作方通过与研发实力较强的公司开展业务合作，提高产能利用率，加快固定资产投资回报，提升盈利水平。故双方的业务合作是基于行业背景及企业现实情况的互利优选。
　　报告期内各期，合作方成都天台山、普德药业除生产公司产品外，也生产其他针剂产品，公司的合作产品占合作方成都天台山、普德药业生产总额的比例较低；同时，公司与成都天台山、普德药业均为正常独立经营的市场主体，双方资产、人员、财务相互独立，双方股东、董事、监事及高级管理人员之间无关联关系。业务合作定价系双方公平协商确定，双方结算价格客观公允。
　　其中，关于CX3002产品技术服务收入的收入确认情况如下：
　　2017年12月，浙江亚太与公司签署了技术开发（合作）合同，并向公司支付首付款500万元，2018年8月，公司协助浙江亚太取得了伦理批件，并于同年9月收到500万元款项，随即公司确认了1,000万元技术服务收入。
　　2019年CX3002项目知识产权变更工作已完成、并已启动药学补充研究和技术转移工作，因此公司确认相关技术服务收入750万元。
　　3、主营业务收入按地域分析
　　报告期内公司销售区域覆盖范围广，在全国各个区域均有销售，并已进入海外市场；公司来自各主要区域的销售收入比例相对保持稳定，各主要区域的销售收入均保持了增长，与公司业务规模不断扩大趋势保持一致。
　　4、主营业务收入的季节性分析
　　报告期内各期公司分季度的营业收入占比相对保持稳定，不存在较大的季节性波动的风险。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。